MDM2 inhibition in MF

MDM2 inhibitors in myelofibrosis treatment: the addition of navtemadlin to ruxolitinibПодробнее

Ronald Hoffman, MD - Drivers of Progression of MPNsПодробнее

Why should we target MDM2 with small molecule inhibitor KRT-232 in patients with MF?Подробнее

KRT-232: a novel MDM2 inhibitor approach in myelofibrosisПодробнее

Inhibiting MDM2 to promote apoptosis in ALLПодробнее

Bridging Micro- and Macroscopic Mechanisms of p53-MDM2 Binding Using Mol. Simulations & Kinetic...Подробнее

Drugs under investigation for patients with MF who have failed treatment with JAK inhibitorsПодробнее

Navtemadlin and its role in the treatment of R/R myelofibrosisПодробнее

Interaction of p53 and Mdm2Подробнее

How effective is pacritinib in managing symptoms and splenomegaly in cytopenic patients with MF?Подробнее

The future of JAK inhibition in myelofibrosisПодробнее

The mechanism of action of navtemadlin and its role in MFПодробнее

An update on the use of navtemadlin in myelofibrosisПодробнее

Ruxolitinib combinations in patients with myelofibrosisПодробнее

What effect does idasanutlin have on TP53-mutated clones in patients with polycythemia vera?Подробнее

Advancements in combination strategies with JAK inhibitors for myelofibrosisПодробнее

Novel targets and combinations being explored in MPNsПодробнее

Unmet needs in MF: managing anemia & improving the efficacy of first and second-line treatmentsПодробнее

Future therapies for MF: pacritinib, momelotinib, fedratinib & other pathwaysПодробнее